EyePoint Pharmaceuticals, a leading company dedicated to developing innovative therapies for serious retinal diseases, has successfully finished enrolling patients in its Phase 3 pivotal program for DURAVYU in the treatment of wet age-related macular degeneration (wet AMD). With both the LUGANO and LUCIA trials now fully enrolled, totaling over 800 patients, EyePoint is on track to deliver groundbreaking results in the global retinal community. The strong safety profile observed in previous clinical trials, coupled with the enthusiastic response from patients and physicians, highlights the potential for DURAVYU to revolutionize the treatment landscape for wet AMD. Stay tuned for the anticipated topline data release in mid-2026, as EyePoint continues to lead the way in bringing innovative therapies to patients in need.
Read more from finance.yahoo.com